Trial · NCT01808313
Results by group328
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 328
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12 | Ambrisentan | 53.59 | Standard Deviation 64.494 | Meters | |
| Change From Baseline in 6MWT at Week 24 | Ambrisentan | 64.36 | Standard Deviation 91.173 | Meters | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Improved by 2 classes at Week 12 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Improved by 1 class at Week 12 | 44 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Not changing at Week 12 | 84 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Worsened by 1 class at Week 12 | 4 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Worsened by 2 classes at Week 12 | 1 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Improved by 2 classes at Week 24 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Improved by 1 class at Week 24 | 51 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Not changing at Week 24 | 77 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Worsened by 1 class at Week 24 | 3 | Participants | |
| Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24 | Ambrisentan | Worsened by 2 classes at Week 24 | 2 | Participants | |
| Change From Baseline in the Borg Dyspnea Index (BDI) at Weeks 12 and 24 | Ambrisentan | Week 12 | -0.34 | Standard Deviation 1.521 | scores on a scale |
| Change From Baseline in the Borg Dyspnea Index (BDI) at Weeks 12 and 24 | Ambrisentan | Week 24 | -0.22 | Standard Deviation 1.952 | scores on a scale |
| Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Weeks 12 and 24 | Ambrisentan | Week 12, n=123 | 0.44 | Standard Deviation 2.687 | log(ng/L) |
| Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Weeks 12 and 24 | Ambrisentan | Week 24, n=122 | 0.37 | Standard Deviation 3.103 | log(ng/L) |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | Death at Week 12 | 2 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | Lung Transplant at Week 12 | 0 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | Hospitalization for PAH at Week 12 | 0 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | Atrial Septostomy at Week 12 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01808313/results